Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)
Authors:
- Fredrick R. SchumacherFSFredrick R. Schumacher
- David CoxDCDavid Cox
- Ruth C. TravisRTRuth C. Travis
- Demetrius AlbanesDADemetrius Albanes
- Naomi E. AllenNANaomi E. Allen
- Gerald AndrioleGAGerald Andriole
- Sonja I. BerndtSBSonja I. Berndt
- Heiner BoeingHBHeiner Boeing
- H. Bas Bueno-De-MesquitaHBH. Bas Bueno-De-Mesquita
- E. David CrawfordECE. David Crawford
- W. Ryan DiverWDW. Ryan Diver
- 1 March 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 21 (3) , 437-444
Abstract
Background: One of the goals of personalized medicine is to generate individual risk profiles that could identify individuals in the population that exhibit high risk. The discovery of more than two-dozen independent single-nucleotide polymorphism markers in prostate cancer has raised the possibility for such risk stratification. In this study, we evaluated the discriminative and predictive ability for prostate cancer risk models incorporating 25 common prostate cancer genetic markers, family history of prostate cancer, and age. Methods: We fit a series of risk models and estimated their performance in 7,509 prostate cancer cases and 7,652 controls within the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). We also calculated absolute risks based on SEER incidence data. Results: The best risk model (C-statistic = 0.642) included individual genetic markers and family history of prostate cancer. We observed a decreasing trend in discriminative ability with advancing age (P = 0.009), with highest accuracy in men younger than 60 years (C-statistic = 0.679). The absolute ten-year risk for 50-year-old men with a family history ranged from 1.6% (10th percentile of genetic risk) to 6.7% (90th percentile of genetic risk). For men without family history, the risk ranged from 0.8% (10th percentile) to 3.4% (90th percentile). Conclusions: Our results indicate that incorporating genetic information and family history in prostate cancer risk models can be particularly useful for identifying younger men that might benefit from prostate-specific antigen screening. Impact: Although adding genetic risk markers improves model performance, the clinical utility of these genetic risk models is limited. Cancer Epidemiol Biomarkers Prev; 21(3); 437–44. ©2012 AACR.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Polygenic susceptibility to prostate and breast cancer: implications for personalised screeningBritish Journal of Cancer, 2011
- Personalized estimates of breast cancer risk in clinical practice and public healthStatistics in Medicine, 2011
- Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk PredictionCirculation, 2011
- Genetic Correction of PSA Values Using Sequence Variants Associated with PSA LevelsScience Translational Medicine, 2010
- Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancerThe Prostate, 2010
- The Genetic Interpretation of Area under the ROC Curve in Genomic ProfilingPLOS Genetics, 2010
- Value of Adding Single-Nucleotide Polymorphism Genotypes to a Breast Cancer Risk ModelJNCI: Journal of the National Cancer Institute, 2009
- Estimating the benefits of PSA screeningNature Reviews Urology, 2009
- Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate CancerJournal of Clinical Oncology, 2009
- Polygenes, Risk Prediction, and Targeted Prevention of Breast CancerNew England Journal of Medicine, 2008